Fresenius Group Overview

03. Mai 2019

Fresenius Kabi führt Biosimilar-Adalimumab IDACIO® in Deutschland ein

Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.